AMACR 1A is a prostate cancer drug target [1,2,4,5,6,7,8] and is an MCR homologue with 43% sequence identity [11], but it has no reported crystal structures and there are challenges associated with it production. This evidence concerns the gene NR3C2 and prostate cancer.